Ethypharm is a specialty pharmaceutical company that focuses on developing and commercializing medications for Central Nervous System (CNS) disorders, including severe pain and opioid dependency, as well as a wide range of high-quality injectable medicines for hospitals and emergency situations. The company serves healthcare providers, hospitals, and patients globally, with a significant presence in Europe, the U.S., and China. Ethypharm operates six state-of-the-art manufacturing plants located in France, the UK, Spain, and China, ensuring a robust supply chain for its products. The company has transitioned from relying on partners for commercialization to selling directly in key markets like France and the UK since 2015. Ethypharm's business model revolves around the development, production, and direct sale of its pharmaceutical products, generating revenue through these channels. The company is also open to partnerships to expand its product portfolio and geographical reach. Ethypharm's management team is committed to innovation and growth, continuously seeking opportunities to enhance its development pipeline and market presence. The company's international footprint and diverse talent pool reflect its strategic ambitions and commitment to making a difference in patients' lives by providing the right treatment at the right time with the right support.

Keywords: CNS disorders, opioid dependency, hospital injectables, pharmaceutical development, healthcare providers, global presence, state-of-the-art plants, direct sales, innovation, strategic partnerships.